Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments
I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
VEGF
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT02873962IIPartially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT04919629IIRecurrent ovarian cancer with symptomatic ascites or pleural effusionRandomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant EffusionNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
APL-2C3-targeted complement inhibitor APL-2Blocks the cleavage of C3Approved in Other Indications
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05231122IIRecurrent serous, endometrioid or clear cell ovarian cancerRandomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian CancerNY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
CDX-1140Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune responseClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03872947IbRecurrent ovarian cancerA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsAZ, CA, LA, NJ, NY, OR, TX, VA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
TRK-950monoclonal antibody TRK-950Undisclosed mechanismClinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.